Protagenic Therapeutics Files 8-K Amendment
Ticker: PTIXW · Form: 8-K/A · Filed: Sep 17, 2025 · CIK: 1022899
| Field | Detail |
|---|---|
| Company | Protagenic Therapeutics, Inc.\New (PTIXW) |
| Form Type | 8-K/A |
| Filed Date | Sep 17, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: amendment, financial-statements, exhibits
Related Tickers: PTIX
TL;DR
Protagenic Therapeutics filed an amendment to its 8-K on May 15, 2025, updating financial statements and exhibits.
AI Summary
Protagenic Therapeutics, Inc. filed an amendment (Amendment No. 2) on September 17, 2025, to its Form 8-K originally filed on May 15, 2025. This amendment pertains to financial statements and exhibits related to the company's reporting period ending May 15, 2025.
Why It Matters
This filing provides updated financial information and exhibits for Protagenic Therapeutics, Inc., which is crucial for investors to assess the company's financial health and recent developments.
Risk Assessment
Risk Level: low — This is a routine amendment to a previous filing, primarily updating financial statements and exhibits, and does not appear to introduce new significant risks.
Key Players & Entities
- Protagenic Therapeutics, Inc. (company) — Filer
- May 15, 2025 (date) — Earliest Event Reported Date
- September 17, 2025 (date) — Filing Date
- Amendment No. 2 (document_part) — Type of filing
FAQ
What is the purpose of this 8-K/A filing?
This filing is an amendment (Amendment No. 2) to a previously filed Form 8-K, specifically to update financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported was on May 15, 2025.
What is the filing date of this amendment?
This amendment was filed on September 17, 2025.
What is the company's exact name as specified in its charter?
The company's exact name is Protagenic Therapeutics, Inc.
What is the state of incorporation for Protagenic Therapeutics, Inc.?
The company is incorporated in Delaware.
Filing Stats: 626 words · 3 min read · ~2 pages · Grade level 11.7 · Accepted 2025-09-17 12:21:47
Filing Documents
- form8ka.htm (8-K/A) — 45KB
- ex23-1.htm (EX-23.1) — 5KB
- ex23-1_001.jpg (GRAPHIC) — 9KB
- ex23-1_002.jpg (GRAPHIC) — 7KB
- 0001493152-25-013851.txt ( ) — 279KB
- ptix-20250515.xsd (EX-101.SCH) — 3KB
- ptix-20250515_def.xml (EX-101.DEF) — 26KB
- ptix-20250515_lab.xml (EX-101.LAB) — 36KB
- ptix-20250515_pre.xml (EX-101.PRE) — 25KB
- form8ka_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized. PROTAGENIC THERAPEUTICS, INC. Date: September 17, 2025 By: /s/ Alexander K. Arrow Name: Alexander K. Arrow Title: Chief Financial Officer